FLT3 and acute myeloid leukemia: In this randomized study (Cephalon 204 study), subjects with FLT3 mutant AML received chemotherapy alone (n = 106) or chemotherapy followed by lestaurtinib (n = 111), achieving a CR + CR with incomplete platelet recovery (CRp) in 21% and 26% of cases, respectively [55].